Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?
4 February 2021
New research, led by Melanoma Institute Australia, has revealed that cancer patients treated with immunotherapy are not at a higher risk of developing severe COVID-19 infection compared to other cancer patients.
With more than 100 million* global cases of COVID-19 infection and the pandemic ongoing, this important finding will have implications for clinical decision-making in patients being treated with immunotherapy for cancer, including melanoma.
‘Previous studies have found that cancer patients infected with COVID-19 are more likely to develop a severe form of the illness and succumb to the disease compared to those without cancer,’ said first study author Dr Aljosja Rogiers, MIA’s Cameron Medical Oncology Fellow. ‘However, it was not known if patients with cancer on immunotherapy would have an increased or decreased risk of severe COVID-19, and this warranted investigation.’
Immunotherapy works by releasing the brakes on the immune system so that it can effectively target and destroy cancer cells. Knowing that immune cells can help fight viruses too meant that it was theoretically possible that immunotherapy may be helpful in reducing the severity of COVID-19 in patients with cancer.
However, immune cells release cytokines which increases inflammation: this has the potential to make the course of a COVID-19 infection worse. This clinical conundrum needed to be investigated to help guide treatment choices for clinicians during the pandemic.
Together with their international collaborators, the researchers found that treatment with immunotherapy does not further increase the risk of developing severe COVID-19 infection in patients with cancer. Their findings were recently published in the Journal for ImmunoTherapy of Cancer.
Publication: Rogiers A, Pires da Silva I, Tentori C, Tondini CA, Grimes JM, Trager MH, Nahm S, Zubiri L, Manos M, Bowling P, Elkrief A, Papneja N, Vitale MG, Rose AAN, Borgers JSW, Roy S, Mangana J, Pimentel Muniz T, Cooksley T, Lupu J, Vaisman A, Saibil SD, Butler MO, Menzies AM, Carlino MS, Erdmann M, Berking C, Zimmer L, Schadendorf D, Pala L, Queirolo P, Posch C, Hauschild A, Dummer R, Haanen J, Blank CU, Robert C, Sullivan RJ, Ascierto PA, Miller WH Jr, Stephen Hodi F, Suijkerbuijk KPM, Reynolds KL, Rahma OE, Lorigan PC, Carvajal RD, Lo S, Mandala M, Long GV. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. J Immunother Cancer. 2021 Jan;9(1):e001931.
*Update data from Johns Hopkins Coronavirus Resource Center. COVID-19 Map. Available: https://coronavirus.jhu.edu/map.html [Accessed 3 Feb 2021].
Former Executive Director of Melanoma Institute Australia Professor John Thompson awarded the prestigious 2018 RPA Foundation Research Medal.
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for pembrolizumab.
The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world.
Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).
It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’.
A new study from The University of Sydney shows that sunscreen reduces melanoma risk by 40 per cent when used from a young age.
Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment.
When David lost his life last year, he was 33, with three daughters under six.
Clinical trials are just that – trials in a clinical setting to evaluate the effectiveness or otherwise of individual and combination treatments.
Melanoma Institute Australia scooped the award pool at the Annual Scientific Meeting of the International Academy of Pathology.
Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.
An American study has discovered a link between early detection and marital status in melanoma diagnosis.
An international course on melanoma pathology in Paris, France co-directed by Professor Richard Scolyer took place over the weekend.
Professor Richard Scolyer highlights the difficulties of diagnosis following the Australian Story feature program on Emma Betts.
Cancer Australia releases 'stage at diagnosis' data for top five incidence cancers – including melanoma
For the first time in Australia, national data has been released on cancer stage at diagnosis. This data explores the top five incidence cancers – female breast cancer, colorectal, lung, prostate cancers and melanoma.
'Dear Emma' - a tribute to the life and times of a young woman determined to raise awareness about melanoma.
Carole Renouf, CEO for MIA thanks Toyota for helping fuel ongoing melanoma research.
Fraser Dykes tackled the Kokoda Trail on an eight day trek in memory of his friend Mark 'Bod' Boddison.
Harvard’s Clinical Professor Martin Mihm and MIA’s Conjoint Medical Director Professor Richard Scoyler delivered a series of lectures on melanoma pathology in Vancouver, British Colombia this week at the world’s biggest annual pathology meeting.